Description de l'entreprise
PAION AG is a publicly listed Specialty Pharmaceutical Company headquartered in Aachen (Germany) with further sites in Cambridge (United Kingdom) and New Jersey (USA). PAION's lead substance, Remimazolam, is an intravenous ultra-short-acting anesthetic that is currently in Phase III clinical development for procedural sedation and general anesthesia. Remimazolam has been investigated in more than 1,000 patients worldwide. Remimazolam is designed to complement and improve currently available treatment options for patients requiring sedation and anesthesia. PAION is focusing its clinical development activities on Remimazolam and has initiated pre-commercial activities according to PAION's vision to become an acknowledged “PAIONeer” in sedation and anesthesia.
Conseil d'administration & Conseil de surveillance
| PDG |
| Gregor Siebert |
| Conseil d'administration |
| Sebastian Werner |
| Conseil de surveillance |
| Dr. Karin Louise Dorrepaal, Dr. Markus Leyck Dieken, Dr. Hans Christoph Tanner |
Données de l'entreprise
| Nom: |
PAION AG |
| Adresse: |
Heussstraße 25,D-52078 Aachen |
| Téléphone: |
+49-241-4453-0 |
| Fax: |
+49-241-4453-100 |
| Courriel: |
info@paion.de
|
| Internet: |
www.paion.de/ |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
88.12% |
| IPO date: |
10/02/2005 |
Relations avec les investisseurs
| Nom: |
Ralf Penner |
| Téléphone IR: |
+49-241-4453-152 |
| IR-Fax: |
+49-241-4453-523 |
| E-mail IR: |
investor.relations@paion.com
|
